India’s digital care ecosystem for chronic condition management, New Delhi-based BeatO has launched a flash glucose monitoring (FGM) programme for better data-driven prevention, control and reversal of diabetes. This will enable users to better assess their relationship with food and get targeted diet, lifestyle and medication counselling from BeatO’s team of doctors and experts based on their FGM data. 

A flash glucose monitor uses a sensor that is placed on the back of the upper arm and worn externally by the user, allowing glucose information to be monitored using an FGM reader. Data from the FGM will enable healthcare professionals at BeatO to observe trends and provide patient-specific insights to achieve targeted HbA1c levels. BeatO will be using the FGM devices of Abbott, the world leader in sensor-based technology.

Speaking on the launch, Gautam Chopra, Co-founder & CEO, BeatO said “Abbott’s world-leading Flash Glucose Monitoring technology with BeatO’s app ecosystem will give our members precise data, along with actionable insights to effectively prevent, control or reverse their diabetes. Our FGM enabled programme is an extension of our vision to empower our members with the right decision-making support for their health”

The integration of the FGM with BeatO’s app ecosystem will enable holistic patient management which will help users to understand their relationship with food vis-à-vis glucose fluctuations like hypoglycemia, hyperglycemia and overall take better control of their condition.